Candice Delcourt1, Shihong Zhang1, Hisatomi Arima1, Shoichiro Sato1, Rustam Al-Shahi Salman1, Xia Wang1, Leo Davies1, Christian Stapf1, Thompson Robinson1, Pablo M Lavados1, John Chalmers1, Emma Heeley1, Ming Liu1, Richard I Lindley1, Craig S Anderson2. 1. From the Neurology Department, Royal Prince Alfred Hospital, Sydney, Australia (C.D., L.D., C.S.A.); Neurological and Mental Health Division, The George Institute for Global Health, Sydney, New South Wales, Australia (H.A., S.S., X.W., J.C., E.H., R.I.L.); Department of Neurology, West China Hospital, Sichuan University, Chengdu, China (S.Z., M.L.); Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (R.A.-S.S.); Division of Clinical Neurosciences, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Département de Neurosciences, Université de Montréal, Montréal, QC, Canada (C.S.); Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease, University of Leicester, Leicester, United Kingdom (T.R.); Unidad de Neurología vascular, Servicio de Neurología, Departamento de Medicina, Clínica Alemana, Santiago, Chile (P.M.L.); Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile (P.M.L.); and Department of Medicine, Westmead Hospital Clinical School, Westmead, New South Wales, Australia (R.I.L.). 2. From the Neurology Department, Royal Prince Alfred Hospital, Sydney, Australia (C.D., L.D., C.S.A.); Neurological and Mental Health Division, The George Institute for Global Health, Sydney, New South Wales, Australia (H.A., S.S., X.W., J.C., E.H., R.I.L.); Department of Neurology, West China Hospital, Sichuan University, Chengdu, China (S.Z., M.L.); Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (R.A.-S.S.); Division of Clinical Neurosciences, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Département de Neurosciences, Université de Montréal, Montréal, QC, Canada (C.S.); Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease, University of Leicester, Leicester, United Kingdom (T.R.); Unidad de Neurología vascular, Servicio de Neurología, Departamento de Medicina, Clínica Alemana, Santiago, Chile (P.M.L.); Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile (P.M.L.); and Department of Medicine, Westmead Hospital Clinical School, Westmead, New South Wales, Australia (R.I.L.). canderson@georgeinstitute.org.au.
Abstract
BACKGROUND AND PURPOSE: In patients with acute intracerebral hemorrhage (ICH), the shape and density of the hematoma are associated with its subsequent growth, but the impact of these parameters on clinical outcome is uncertain. METHODS: Baseline computed tomographic scans and clinical data were obtained in the Intensive Blood Pressure Reduction in Acute Intracerebral Hemorrhage Trial (INTERACT2). Three independent neurologists blind to clinical data assessed ICH for shape and density using a previously described scale. Shape was defined as irregular when the ICH had ≥2 extra lesions added to the ellipsoid-shaped ICH. Density was heterogeneous when there were ≥3 low-density lesions within the ICH. Outcome measures were death and major disability (modified Rankin scale score of 3-5), combined and separate at 90-day postrandomization. Multivariable logistic regression models were used to determine the significance of hematoma characteristics on outcome. RESULTS: There were 2066 patient computed tomographic scans included in the analysis, with 46% and 38% having irregular and heterogeneous ICH, respectively. Irregular shape was independently associated with death/major disability (adjusted odds ratio, 1.60; 95% confidence interval [CI], 1.29-1.98) and major disability alone (adjusted odds ratio, 1.60; 95% CI, 1.31-1.95), but not with death alone (adjusted odds ratio, 0.97; 95% CI, 0.68-1.39). Heterogeneous density was not associated with clinical outcomes (adjusted odds ratio, 1.06; 95% CI, 0.85-1.33), 1.04 (95% CI, 0.73-1.48), and 1.14 (95% CI, 0.93-1.39), respectively, for death/major disability, death alone, and disability alone). CONCLUSIONS: Irregular shape, but not heterogeneous density, is independently associated with poor outcome after ICH. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.
BACKGROUND AND PURPOSE: In patients with acute intracerebral hemorrhage (ICH), the shape and density of the hematoma are associated with its subsequent growth, but the impact of these parameters on clinical outcome is uncertain. METHODS: Baseline computed tomographic scans and clinical data were obtained in the Intensive Blood Pressure Reduction in Acute Intracerebral Hemorrhage Trial (INTERACT2). Three independent neurologists blind to clinical data assessed ICH for shape and density using a previously described scale. Shape was defined as irregular when the ICH had ≥2 extra lesions added to the ellipsoid-shaped ICH. Density was heterogeneous when there were ≥3 low-density lesions within the ICH. Outcome measures were death and major disability (modified Rankin scale score of 3-5), combined and separate at 90-day postrandomization. Multivariable logistic regression models were used to determine the significance of hematoma characteristics on outcome. RESULTS: There were 2066 patient computed tomographic scans included in the analysis, with 46% and 38% having irregular and heterogeneous ICH, respectively. Irregular shape was independently associated with death/major disability (adjusted odds ratio, 1.60; 95% confidence interval [CI], 1.29-1.98) and major disability alone (adjusted odds ratio, 1.60; 95% CI, 1.31-1.95), but not with death alone (adjusted odds ratio, 0.97; 95% CI, 0.68-1.39). Heterogeneous density was not associated with clinical outcomes (adjusted odds ratio, 1.06; 95% CI, 0.85-1.33), 1.04 (95% CI, 0.73-1.48), and 1.14 (95% CI, 0.93-1.39), respectively, for death/major disability, death alone, and disability alone). CONCLUSIONS: Irregular shape, but not heterogeneous density, is independently associated with poor outcome after ICH. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.
Authors: Gregoire Boulouis; Andrea Morotti; H Bart Brouwers; Andreas Charidimou; Michael J Jessel; Eitan Auriel; Octavio Pontes-Neto; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Jonathan Rosand; Anand Viswanathan; Mahmut E Gurol; Steven M Greenberg; Joshua N Goldstein Journal: Stroke Date: 2016-09-06 Impact factor: 7.914
Authors: Gregoire Boulouis; Andrea Morotti; Andreas Charidimou; Dar Dowlatshahi; Joshua N Goldstein Journal: Stroke Date: 2017-03-13 Impact factor: 7.914
Authors: Elena Serrano; Antonio López-Rueda; Javier Moreno; Alejandro Rodríguez; Laura Llull; Christian Zwanzger; Laura Oleaga; Sergi Amaro Journal: Eur Radiol Date: 2021-06-20 Impact factor: 5.315
Authors: Stefan P Haider; Adnan I Qureshi; Abhi Jain; Hishan Tharmaseelan; Elisa R Berson; Tal Zeevi; Shahram Majidi; Christopher G Filippi; Simon Iseke; Moritz Gross; Julian N Acosta; Ajay Malhotra; Jennifer A Kim; Lauren H Sansing; Guido J Falcone; Kevin N Sheth; Seyedmehdi Payabvash Journal: Eur J Neurol Date: 2021-07-18 Impact factor: 6.288